Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) NEW YORK, December 6, 2023—Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. The firm… Read More »Cerevel Therapeutics Holdings, Inc.